New Report Highlights That the Czech Republic Could Serve as a Model for the EU in Addressing Smoking Prevalence
10.6.2022 07:00:00 EEST | Business Wire | Press release
Ahead of the start of the Czech Presidency of the Council of the EU in July, the think tank Centre for Economic and Market Analysis (CETA) published the comparative study “A new approach towards tobacco legislation: the case for harm reduction in CEE and the EU” at an event in Prague. It presents a new measure, the so-called ‘Harm Reduction Index’ which ranks EU Member States according to their ability to implement the concept of risk reduction.
Yesterday, an event organised by the Czech think tank Centre for Economic and Market Analysis (CETA) brought together medical and addiction experts in Prague to discuss how a tobacco-free generation, where less than 5% of EU-citizens use tobacco, can be achieved by 2040. They concluded that the objectives laid out in Europe’s Beating Cancer Plan cannot be attained under current circumstances and that a revised tobacco control policy based on scientific evidence is needed.
"If the European Commission is serious about its plans to reduce the number of smokers and the impact of smoking, it must start considering the concept of risk reduction in the area of smoking,” Czech National Drug Coordinator Mgr. Jindřich Vobořil highlighted at the event. “The Czech Government has committed itself to this approach in its programme statement for the upcoming Presidency. I will also promote it in relation to the ongoing evaluation of the Tobacco Products Directive, which is an effective policy to achieve a real reduction in the number of smokers of conventional cigarettes,” he added.
"The data show that the abstinence approach is inadequate. The solution for smokers is to switch to less harmful alternatives," agreed Assoc. Ernest Groman, MD, from the Vienna Nicotine Institute. The only European country close to the 5% target is Sweden. According to the experts, the low number of smokers is mainly due to the availability of less harmful alternatives.
Assoc. MUDr. Viktor Mravčík, Ph.D added that, "The harm reduction approach should be implemented by the European Commission in the context of Europe’s Beating Cancer Plan and the revision of the Tobacco Products Directive.”
"According to the Harm Reduction Index, the Czech Republic ranks second among the countries compared. The Czech government should use the upcoming Presidency to undertake a comprehensive review of tobacco dependence policies based on science rather than emotion,” CETA Research Director Ing. Aleš Rod, Ph. D. and member of the Advisory Board to the Czech Government concluded.
About CETA:
The Centre for Economic and Market Analysis (CETA) is a non-governmental, non-profit organisation that aims to analyse market, socio-economic and political phenomena and highlight their impacts.
The Institute for Rational Addiction Policies is a multidisciplinary association of independent and distinguished experts who are dedicated to research and education in the field of addiction from all perspectives.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220609006003/en/
Contact information
Aleš Rod
ales.rod@eceta.cz
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EOS and VOP CZ Sign Memorandum of Understanding to Explore Cooperation on Czech Programmes22.10.2026 10:00:00 EEST | Press release
EOS Defence Systems (EOS) and VOP CZ have signed a Memorandum of Understanding (MoU) at Future Forces Forum in Prague to explore cooperation on wheeled armoured vehicle programmes for the Czech Army and other future defence projects in the Czech Republic and Europe where VOP CZ is involved. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021408045/en/ EOS and VOP CZ sign a Memorandum of Understanding at Future Forces Forum in Prague. Left to right: Martin van de Voorde, Sales Director Europe, EOS; Vlastimil Navrátil, Managing Director, VOP CZ; Pavla Ungrová, Sales Director, VOP CZ; Rear Admiral Richard Caton, Australia’s Military Representative to NATO and the EU; Group Captain Michael Schleeman, Australia’s Defence Attaché; and Matej Pupák, Program Lead, VOP CZ. The agreement brings together EOS' expertise in advanced remote weapon systems (RWS) with VOP CZ's established capabilities in military vehicle integration, produ
Ferrer and Prilenia Announce Authorization for EU Initiation of Confirmatory PRECISE-HD Study of Pridopidine in Huntington's Disease22.10.2026 10:00:00 EEST | Press release
Ferreri and Prilenia Therapeutics B.V.today announced that the confirmatory Phase 3 PRECISE-HD study of investigational pridopidine in Huntington's disease (HD) has received authorization to begin in participating EU Member States (EU CT number: 2026-526093-16-00, NCT07609108). Recruitment in the EU is expected to commence this month, joining currently recruiting sites in the US and UK, with Canada to follow. Designed to evaluate the efficacy and safety of pridopidine (administered as an oral capsule twice a day), and to generate data for regulatory evaluation, the global, approximately 400-participant, randomized, double-blind, placebo-controlled PRECISE-HD study will assess the clinical effect of the investigational treatment on disease progression, functional capacity, motor function, cognition, speech and quality of life. “The initiation of PRECISE-HD in Europe marks a milestone for the Huntington’s disease research community. This confirmatory Phase 3 study has been designed to bu
IQM Quantum Computers Announces Conference Call to Report Third Quarter 2026 Financial Results on November 5, 202622.10.2026 09:00:00 EEST | Press release
As published previously, IQM Quantum Computers Plc (Nasdaq: IQMX) ("IQM" or the "Company"), a global leader in superconducting quantum computers, will report financial results for the third quarter 2026 on Thursday, November 5, 2026. CEO Dr. Jan Goetz and CFO Jan Kuerschner will host a conference call at 3:00 PM EET / 2:00 PM CET / 8:00 AM EST on the same day followed by a Q&A session with analysts. Conference Call and Webcast A live audio webcast of the conference call will be available to the public through the link below and can be accessed in the News & Events section of IQM's Investor Relations website at https://investors.iqm.tech/. A replay of the call will be available at the same location for one year following the call. Participation in the Q&A during the conference call will require registration using the link below. Date: Thursday, November 5, 2026 Time: 3:00 PM EET / 2:00 PM CET / 8:00 AM EST Webcast Link: https://edge.media-server.com/mmc/p/syqjnhp6To ask questions on the
Galderma Delivers Net Sales of 4.765 B USD in the First Nine Months, Up 25.1% at Constant Currency Year-on-Year, and Raises Full-Year Net Sales Guidance22.10.2026 08:00:00 EEST | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first nine months of 2026. Record net sales of 4.765 billion USD for thefirst nine months of 2026, representing 25.1% year-on-year growth at constant currency1, predominantly driven by volume and complemented by favorable mix. Broad-based double-digit growth across geographies and product categories, reflecting strong execution of Galderma’s proven integrated dermatology strategy, with stand-out performance in Therapeutic Dermatology, across both Nemluvio and the mature portfolio, as well as in Dermatological Skincare and Neuromodulators. Continued market outperformance across all three product categories, with net sales growth year-on-year at constant currency of 13.2% in Injectable Aesthetics, 16.2% in Dermatological Skincare, and 64.4% in Therapeutic Dermatology (with Nemluvio net sales of 735 million USD). Strengthening Galderma’s dermatology platform, with the pre
Ruler of Ras Al Khaimah Inaugurates the First Ras Al Khaimah’s Business Consultancy in China, Strengthening Ties With Guangdong22.10.2026 00:46:00 EEST | Press release
HH Sheikh Saud bin Saqr Al Qasimi, UAE Supreme Council Member and Ruler of Ras Al Khaimah, inaugurated the Emirate’s first business consultancy in China, marking a new chapter of cooperation and partnership. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021542126/en/ His Highness Sheikh Saud bin Saqr Al Qasimi, UAE Supreme Council Member and Ruler of Ras Al Khaimah, inaugurated the Emirate’s first business consultancy in China, located in Guangzhou, Guangdong Province, stating that the launch reflects a long-term commitment to strengthening ties with partners in China and to creating new avenues for investment, trade and collaboration. (Photo: AETOSWire) Located in the industrial hub of Guangzhou, the consultancy will serve as a leading platform dedicated to strengthening Ras Al Khaimah’s engagement with Chinese businesses, facilitating expanding cooperation across key sectors. The inauguration builds on a relationship t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
